SymbolZYME
NameZYMEWORKS INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1385 WEST 8TH AVENUE,SUITE 540, VANCOUVER, British Columbia, V6H 3V9, Canada
Telephone+1 604 678-1388
Fax
Email
Websitehttps://www.zymeworks.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001937653
Description

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Additional info from NASDAQ:
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

2026-08-11 10:00

Zymeworks Announces Participation in Upcoming Investor Conferences

Read more
2026-07-16 10:00

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Read more
2026-07-06 21:29

Hollywood Mark 🟢 acquired 939 shares of Zymeworks Inc. (ZYME) at $22.22 Transaction Date: Jul 06, 2026 | Filing ID: 000009

Read more
2026-06-29 11:20

(10% Negative) ZYMEWORKS INC. (ZYME) Announces Business Combination

Read more
2026-06-29 10:00

Zymeworks to Acquire Theravance Biopharma, Inc.

Read more
2026-06-14 22:05

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Read more
2026-05-15 21:00

Schneider Paul R 🟢 acquired 297.0K shares (2 derivative) of Zymeworks Inc. (ZYME) at $24.57 ($4.4M) Transaction Date: May 13, 2026 | Filing ID: 227140

Read more
2026-05-15 17:55

New Form 3 - Zymeworks Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-227111 <b>Size:</b> 15 KB

Read more
2026-05-15 17:14

New Form SCHEDULE 13G/A - Zymeworks Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062529 <b>Size:</b> 10 KB

Read more
2026-05-14 20:29

(10% Negative) ZYMEWORKS INC. (ZYME) Announces Business Combination

Read more